trial

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

NCTId NCT00139919
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment —
Sponsored by Solvay Pharmaceuticals
Primary completion 2007-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
—
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2006-01
Primary completion
2007-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Bifeprunox

Sponsors

Solvay PharmaceuticalsLead Sponsor
H. Lundbeck A/SCollaborator
Wyeth is now a wholly owned subsidiary of PfizerCollaborator

Investigators

1
Global Clinical Director SolvayStudy Director

Sites

1 total
Orange, United States

Linked catalysts

1
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schi — primary completion2007-10

Facts & assertions

3 sourced
Phase
PHASE2
Primary Completion Date
2007-10
Status
COMPLETED
relationships
The graph out of here
drug
Bifeprunox
drug
lead_sponsor
Solvay Pharmaceuticals
company
collaborator
H. Lundbeck A/S
company
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Bipolar Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Global Clinical Director Solvay
person